This week Nature Medicine published the third in a new fortnightly column called The Clinical Pipeline.
Our goal is to further strengthen the journal's coverage of translational and clinical research, from bench to bedside, and so each column will analyse a recent clinical trial announcement, preprint, or journal publication (with all the caveats that apply to non-peer reviewed research!)
Thiago Carvalho is writing these articles for us, as an experienced Nature Medicine freelancer and author of our COVID Research in Brief articles during the pandemic.
Thiago's first column covered BioNTech’s new combination mRNA / CAR-T cancer vaccine; the second column discussed the unknown efficacy of the antiviral, tecovirimat, against monkeypox; and today's column covers how the FDA are using biomarker data in the approval of new drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
This is something of an experiment for the journal, so please let us know if you found them interesting and/or useful - or any other feedback!
Please sign in or register for FREE
If you are a registered user on Nature Portfolio Health Community, please sign in